ALL enters a quiet stretch before its May 22 earnings call with something rare in a sector under macro scrutiny: a stock that has actually worked and a broker consensus that is being revised upward.
Options positioning tells the most interesting story right now. Demand for downside protection has picked up meaningfully — the put/call ratio climbed to 1.30, well above its 20-day average of 1.17 and running close to the 52-week high of 1.34 hit on April 30. The z-score of 1.70 confirms this isn't noise. With the next earnings print three weeks out, it looks as though some investors are buying insurance on the insurer.
Short interest tells a different story. At 2.79% of the free float, bears have a position — but it's not a conviction trade. What is notable is the pace of the build: short interest has risen 30% over the past month, adding roughly 1.5 million shares. That's a meaningful step-up even if the absolute level remains modest. Borrow conditions remain almost frictionless — cost to borrow is just 0.40% and availability is plentiful — meaning the shorts are not being squeezed and new shorts face no meaningful friction to entering. Days to cover sits near 5.7 days per the official FINRA data, offering shorts a comfortable exit runway. The ORTEX short score is a relatively benign 37.6, ranking in the 34th percentile across the universe — this is not a stock the lending market is flagging as stressed.
The Street has shifted in a notably constructive direction this week. Wells Fargo analyst Elyse Greenspan lifted her target from $229 to $243 this morning while maintaining her Equal-Weight rating — a meaningful 6% raise after Q1 results. Piper Sandler raised its target to $268 from $252 (Overweight), and Citigroup nudged to $226 from $221 (Neutral), both moves filed on May 1. The mean consensus target sits at $241.52 against a close of $218.51, implying roughly 10.5% upside to the Street's central view. There are genuine believers — Mizuho and KBW both carry Outperform ratings with targets in the $260s — alongside holdouts. Barclays keeps an Underweight with a $208 target, sitting below the current price. The bull case rests on accelerating policy-in-force growth in personal auto, strong underwriting, and favorable reserve development. The bears point to a combined ratio of 89.4% running well above the long-term 95% target, competitive pricing pressure in personal lines, and the ever-present tail risk of catastrophe losses that exceed reinsurance limits. EPS momentum is the stand-out factor score at the 98th percentile over 30 days, matching a dividend score also at the 98th percentile — a rare double-top on income and earnings quality metrics. EV/EBIT ranks in the 88th percentile on value, though the forward P/E of 7.7x on consensus EPS of $29.62 is worth anchoring to before drawing valuation conclusions.
On the institutional side, ownership looks stable with passive anchors firmly in place. Vanguard holds 12.9% and BlackRock 8.7%, with State Street adding over 438,000 shares in the most recent quarter — a quiet but notable accumulation from one of the largest passive shops. GQG Partners added nearly 1.5 million shares as of late February, the most aggressive directional buy among the top-15 holders. Insider activity has been consistently on the sell side. The COO sold $4.1 million of stock on May 1. Chairman and CEO Tom Wilson sold in three tranches in mid-March totalling around $3.5 million, following earlier March sales. These are scheduled-looking disposals — individually modest as a percentage of the company — but the 90-day insider net is a $18.9 million outflow across roughly 89,000 shares, a signal worth noting even if trade significance scores remain low.
The setup heading into the May 22 print is one to watch closely. The most recent Q1 print (April 30) generated just a 2% single-day move; the prior print was flat. Whether the mounting options hedging and the gradual short rebuild reflect genuine concern about catastrophe exposure or simply pre-earnings caution in a stock that has gained 5.5% over the past month is the question the next earnings release will answer.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
